Sitravatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Sitravatinib
Accession Number
DB15036
Type
Small Molecule
Groups
Investigational
Description

Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
CWG62Q1VTB
CAS number
1123837-84-2
Weight
Average: 629.68
Monoisotopic: 629.190831934
Chemical Formula
C33H29F2N5O4S
InChI Key
WLAVZAAODLTUSW-UHFFFAOYSA-N
InChI
InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
IUPAC Name
N'1-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
SMILES
COCCNCC1=CC=C(N=C1)C1=CC2=C(S1)C(OC1=C(F)C=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
52083477
ChEMBL
CHEMBL3989926
Wikipedia
Sitravatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentSquamous Cell Carcinoma Mouth / Squamous Cell Carcinoma of the Oral Cavity / Squamous Cell Carcinoma, Head And Neck1
1Active Not RecruitingTreatmentCancer, Advanced1
1RecruitingTreatmentAdvanced Solid Tumors / Non-squamous, Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and Ovarian Cancer (OC)1
1, 2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Malignant Neoplasms of Urinary Tract / Metastatic Kidney Carcinoma / Metastatic Renal Cell Cancer / Other Disorders of Kidney and Ureter / Renal Cell Adenocarcinoma / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer AJCC V71
1, 2RecruitingTreatmentGastric/Gastroesophageal Junction Cancer / Hepatocellular,Carcinoma1
2Not Yet RecruitingTreatmentCarcinoma Breast Stage IV / Metastatic Breast Cancer / Neoplasms, Breast / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentBladder transitional cell carcinoma / Transitional Cell Carcinoma / Urothelial Carcinoma of the Renal Pelvis and Ureter / Urothelial Carcinoma Ureter / Urothelial Carcinoma Urethra1
2RecruitingTreatmentClear Cell Renal Cell Carcinoma1
2RecruitingTreatmentLiposarcoma / Metastatic Liposarcoma1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentMetastatic Non-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000527 mg/mLALOGPS
logP4.49ALOGPS
logP5.33ChemAxon
logS-6.1ALOGPS
pKa (Strongest Acidic)13.17ChemAxon
pKa (Strongest Basic)8.33ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area114.47 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity166.98 m3·mol-1ChemAxon
Polarizability64.71 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:44 / Updated on February 02, 2020 03:19